top of page

Humira patent litigation was resolved between AbbVie and Boehringer Ingelheim

  • Writer: ipharmaservices
    ipharmaservices
  • May 14, 2019
  • 1 min read

Humira has announced that the patent litigation was resolved between AbbVie and Boehringer Ingelheim. Based on the resolution, AbbVie will provide a non-exclusive license to BI in the United States. 

Biosimilar Cyltezo will be available from July 1, 2023. BI will pay royalties for AbbVie. Earlier AbbVie has sued the BI for infringing more than 70 patents in 2017 during the development of adalimumab biosimilar. 

BI follows in the line of Coherus, Pfizer, Amgen, Mylan, Samsung Bioepis, Sandoz, Fresenius Kabi, and Momenta which got the rights for adalimumab biosimilar.

Amgen’s product Amjevita will be the first biosimilar that will be available in the United States market. It will be available from January 2023

Recent Posts

See All

Comments


For sponsored articles, link insertions, and advertisements, please write to info@ipharmacenter.com

Find the latest pharma and healthcare news on Telegram now. Simply scan the QR code. 

Rephrase with Ginger (Cmd+⌥+E)
iPharmaCenter Telegran_edited.jpg
bottom of page